ORIGINAL RESEARCH article
Front. Med.
Sec. Translational Medicine
Volume 12 - 2025 | doi: 10.3389/fmed.2025.1703759
This article is part of the Research TopicMetabolic and Epigenetic Dynamics in Shaping Tumor MicroenvironmentView all articles
Unraveling the Genetic Links Between Obesity or Insulin-Resistance and Breast Cancer through the Impact of CD295 and ITLN1 SNPs with DNA Damage in a Case-Controlled Study with Bioinformatics Analysis #
Provisionally accepted- 1Department of Biochemistry, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt
- 2Future University in Egypt, New Cairo City, Egypt
- 3Faculty of Pharmacy, New Cairo, Egypt
- 4National Cancer Institute, Cairo, Egypt
- 5Mansoura University Faculty of Medicine, Mansoura, Egypt
- 6Imperial College London Institute of Global Health Innovation, London, United Kingdom
- 7King Abdulaziz University Faculty of Medicine, Jeddah, Saudi Arabia
- 8Klinikum Vest GmbH Behandlungszentrum Knappschaftskrankenhaus Recklinghausen, Recklinghausen, Germany
- 9Misr International University Faculty of Pharmacy, Cairo, Egypt
- 10Alexandria University Faculty of Pharmacy, Alexandria, Egypt
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Mutations in the cluster of differentiation (CD) 295 gene, encoding class I cytokine receptor, are associated with obesity and breast cancer (BC). SNPs in the adipocyte-inferred novel cytokine intelectin 1 (ITLN1) remain understudied in connection to CD295 polymorphisms and diabetes mellitus (DM) or a pre-diabetic state, as well as to DNA damage seen in BC. Aim: To explore whether CD295 (rs6700986) and ITLN1 (rs952804) SNPs impact BC with or without DM, insulin resistance (IR) or obesity. Effects of ITLN1 or CD295 polymorphism(s) on DNA damage in BC were also examined. All of these to be confirmed by bioinformatics/in silico analysis. Subjects and Methods: Blood samples from 170 women with BC (including 33 and 48 with DM and pre-diabetes, respectively) and from 108 age-matched women in the control group were collected. Plasma insulin, leptin, CD295, and ITLN1 levels were measured by ELISA. rs6700986 and rs952804 were analyzed by RT-PCR. DNA damage was assessed using alkaline comet assay. Results: BC cases with clinical stage T II and positive LN as well as tumor histologic grade III, presence of obesity, pre-diabetic events, DM or IR were associated with CD295 rs6700986 mutant homozygous (CC) and heterozygous (CT) genotypes and ITLN1 rs952804 mutant heterozygous (CT) genotype (P ≤ 0.05). Tail DNA (%) and tail moment units were significantly associated with CD295 rs6700986 CT and ITLN1 rs952804 TT genotypes. C allele (CT+CC vs. TT) and T allele (TT+CT vs. CC) for CD295 rs6700986 and ITLN1 rs952804, respectively, were associated with BC risk (P ≤ 0.05). Conclusion: CD295 (rs6700986) and ITLN1 (rs952804) SNPs to be considered as BC associated-susceptibility risk factors in obese, insulin-resistant or pre-diabetics.
Keywords: CD295, cytokines/inflammation, breast cancer (BC), polymorphism/mutations, ITLN1, obesity/Insulin resistance (IR)/Diabetes mellitus (DM), Bioinformatics/In Silico
Received: 11 Sep 2025; Accepted: 29 Sep 2025.
Copyright: © 2025 Hamdy, Mosaad, Elshimy, Hady, Lin, Jastaniah, Amjad, Altoukhi, Almarzouki, Abdelsamad. MD. M.Sc. MHBA, El Magdoub and Fathi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Nadia M Hamdy, nadia_hamdy@pharma.asu.edu.eg
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.